Disclosure of Related Party Transactions for Quarter Ended September 30, 2025
Lasa Supergenerics disclosed related party transactions for the quarter and half year ended September 30, 2025, including director remuneration, sitting fees, and donations, as per SEBI regulations.
Disclosure of related party transactions is a routine compliance matter and does not have a significant impact on the company's operations or financials.
The announcement is a routine disclosure of related party transactions, with no indication of positive or negative impact.
* Lasa Supergenerics Limited disclosed related party transactions for the quarter and half year ended September 30, 2025, as per Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. * The transactions include remuneration to directors (Omkar Herlekar, Prathamesh Chalke, Umesh Pawar), sitting fees to independent directors (Ekta Gurnasinghani, Ajay Sukhwani, Hardesh Tolani, Manali Bhagtani, Yogesh Hari Ughada, Pravin Gadalya Lachake, Ketan Bhau Songal, Rekha Hemant Wakh), remuneration to company secretary (Mitti Jain) and CFOs (Ravi Shankar Kabra, Varsha Joshi), and donation to Dr Omkar Herlekar Foundation. * Total value of related party transactions is ₹710.
What to do with a filing like this
Lasa Supergenerics Limited filed this with the NSE as a statutory disclosure, categorised under related party transactions. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lasa Supergenerics Limited. Read the original for the full detail.